FRONTIER BIOTECHNOLOGIES Inc.

Press Releases

   
Home>Media

Aikening® (albuvirtide) Launched in Malaysia

Frontier Biotechnologies and Pahang Pharmacy have signed a partnership agreement for the supply, distribution and marketing of Aikening® in Malaysia. Aikening® is now available in Malaysia.Frontier Biotechnologies announced in September 2022 that the National Pharmaceutical Regulatory Agen...
  • 2023-03-16  09:21:15
details>

Good News | Frontier Biotech’s exclusive patented Product AIKENING® successfully renewed its contract with the National Essential Drug List

On January 18, 2023, the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the National Medical Insurance, Labour Injury Insurance and Maternity Insurance Essential Drug List (2022) [hereafter referred to as the National Essential Drug List (2022...
  • 2023-01-19  13:48:02
details>

Frontier Biotech won the 2022 Biotechnology Innovation Award

On January 12, 2023, the 2nd Huaxia Health Industry Summit Forum and Golden Cane Award Ceremony, co-hosted by China Times, Lanzhou New Area Administrative Committee, was successfully held in Lanzhou. Frontier Biotech (hereinafter referred to as: the company, stock code: 688221.SH) won the "2022...
  • 2023-01-13  13:45:58
details>

Frontier Biotechnologies to Present and Update the Latest Progress of FB2001 Nebulized Aerosol Inhalation formulary at the 2022 China Pharmaceutical CMC Innovation Summit

On December 2, 2022, Dr. Min Hu, the Chief Medical Officer of Frontier Biotechnologies Inc. (the “Company”, stock code: (688221. SH) presented the latest clinical updates of COVID-19 small molecule treatment FB2001 (generic name: Bofutrelvir) for nebulized inhalation at the 2022 China Chemical Pharm...
  • 2022-12-05  09:59:48
details>

FB2001 preclinical data published at Antiviral Research

Frontier Biotechnologies (hereinafter referred to as the company, stock code: 688221. SH) announces that the preclinical data of FB2001 (generic name: Bofutrelvir), was recently published at the international peer-reviewed journal "Antiviral Research". This report highlighted the results o...
  • 2022-11-11  15:02:56
details>

Novel Inhibitor for Treating Hospitalized Patients With COVID-19

  • 2022-11-08  15:01:00
details>

Aikening® (albuvirtide) Granted Approval by the Food and Drug Administration in China for Use as An Intravenous Bolus Injection Improves Convenience and Compliance

Frontier Biotechnologies announced in October 2022, it has obtained approval from the Food and Drug Administration in China for Aikening® (albuvirtide) for use as an intravenous bolus injection, as an additional route of administration.The current route of administration for Aikening® is v...
  • 2022-11-04  14:59:38
details>

Aikening® Unveiled at the Malaysian HIV Forum After Obtaining Marketing Authorization in Malaysia

Frontier Biotechnologies obtained approval for Aikening® (albuvirtide for injection), the first long-acting fusion inhibitor treatment for HIV, from the National Pharmaceutical Regulatory Agency of Malaysia in September 2022. Subsequently, Frontier Biotech partnered Pahang Pharmacy and particip...
  • 2022-10-15  16:18:45
details>

"Our drug is now an important treatment for HIV patients in China"

  • 2022-10-03  16:15:16
details>

Frontier Biotechnologies Announces Approval of Clinical Trial Application for a novel FB2001 Nebulized Aerosol Inhalation formulary to treat COVID-19

Recently, Frontier Biotechnologies (hereinafter referred to as the company, stock code: 688221. SH) received the "Pharmaceutical Clinical Trial Approval Notice" issued by the National Medical Products Administration. The study of FB2001 nebulization inhalation will enroll patients with mil...
  • 2022-09-27  16:14:12
details>

Dr. Changjin Wang, CEO at Frontier Biotechnologies, Shares Insights on P-I Results of its Coronavirus Mpro Inhibitor

  • 2022-09-19  15:52:23
details>

Frontier Biotechnologies Inc. have been included in the list of “China’s Top 30 Small Molecule Pharmaceutical Companies Innovation”

On September 16, 2022, the "2021 China Biopharmaceutical Enterprise Innovation Top 100 Series List" officially announced, Frontier Biotechnologies Inc. (stock code "688221.SH") was once again successfully included as "Chinas Top 30 Small Molecule Pharmaceutical Enterprises I...
  • 2022-09-17  14:57:06
details>

Develop Innovative Therapies to Better Human Lives

Frontier Biotechnologies Inc.（Nanjing）
Medicalinfo@frontierbiotech.com
jubao@frontierbiotech.com
Adverse events report mailbox：pv@frontierbiotech.com
Copyright © 2016 Corporation All Rights ReservedFrontier Biotechnologies Inc.
Full Prescribing Information | Introduction for Use | About Frontier

This site is for informational purposes only
and is intended for Healthcare Professionals.

Are you a Healthcare Professional?

I am a licensed Healthcare Professional I am a Patient or Caregiver